arrow
G

Giulio Sartori

Institute of Oncology Research
H指数:13
被引数:465

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

SAKK 35/14 randomized trial of rituximab with or without ibrutinib for patients with untreated follicular lymphoma

SAKK 35/14随机试验:利妥昔单抗联合或不联合伊布替尼治疗初治滤泡性淋巴瘤患者

2026-09-060
OAAI
IL-16 production is a mechanism of resistance to BTK inhibitors and R-CHOP in lymphomas

IL-16的产生是淋巴瘤对BTK抑制剂和R-CHOP的抵抗机制

Blood
IF23.1
2026-06-020
PRE
Novel PI3kδ inhibitor roginolisib synergizes with venetoclax in hematologic malignancies

Sasi, B.K.; Tarantelli, C.; Martindale, S.; Civanelli, E.; Cannas, E.; Sartori, G.; Arribas, A.J.; Fernandes, S.M.; Shupe, S.J.; Machado, J.H.; 等. 新型PI3kδ抑制剂roginolisib与venetoclax在血液系统恶性肿瘤中具有协同作用。Haematologica 2025. [Google Scholar] [CrossRef] [PubMed]

2025-12-012
OAAI
Chemosensor receptors are lipid-detecting regulators of macrophage function in cancer

化学传感器受体是癌症中巨噬细胞功能的脂质检测调节剂

2025-06-300
OAAI
A first-in-class Wiskott-Aldrich syndrome protein activator with antitumor activity in hematologic cancers
2024-06-201
OAAI
ERBB4-Mediated Signaling Is a Mediator of Resistance to PI3K and BTK Inhibitors in B-cell Lymphoid Neoplasms
2023-10-192
OA
ERBB4-mediated signaling is a mediator of resistance to BTK and PI3K inhibitors in B cell lymphoid neoplasms
2023-04-040
PRE
SAKK 35/15: a phase 1 trial of obinutuzumab in combination with venetoclax in patients with previously untreated follicular lymphoma
2022-07-064
OAAI
Resistance to PI3Kδ inhibitors in marginal zone lymphoma can be reverted by targeting the IL-6/PDGFRA axis
2022-04-289
OAAI